Home Tools
Log in
Cart

Isocitrate Dehydrogenase (IDH)

Isocitrate dehydrogenase (IDH) and is an enzyme that catalyzes the oxidative decarboxylation of isocitrate, producing alpha-ketoglutarate (α-ketoglutarate) and CO2. This is a two-step process, which involves oxidation of isocitrate (a secondary alcohol) to oxalosuccinate (a ketone), followed by the decarboxylation of the carboxyl group beta to the ketone, forming alpha-ketoglutarate. In humans, IDH exists in three isoforms: IDH3 catalyzes the third step of the citric acid cycle while converting NAD+ to NADH in the mitochondria. The isoforms IDH1 and IDH2 catalyze the same reaction outside the context of the citric acid cycle and use NADP+ as a cofactor instead of NAD+. They localize to the cytosol as well as the mitochondrion and peroxisome.
Cat. No. Product name CAS No. Purity Chemical Structure
T7741 DS-1001b 1898207-64-1 98%
DS-1001b is an inhibitor of mutant IDH-1 (Isocitrate Dehydrogenase-1)
T16161 Mutant IDH1 inhibitor 1429180-08-4 98%
Mutant IDH1 inhibitor is an effective inhibitor of mutant IDH1 R132H (IC50: < 72 nM).
T7307 Vorasidenib 1644545-52-7 98%
Vorasidenib is an inhibitor of mutant isocitrate dehydrogenase (IDH; IC50s = 31.9 and 31.7 nM for IDH1R132H and IDH2R140Q, respectively)
T1809 AGI-6780 1432660-47-3 98%
AGI-6780 is a potent and selective inhibitor of IDH2 R140Q mutant.
T2043 Mutant IDH1-IN-1 1355326-21-4 98%
Mutant IDH1-IN-1 is a potent mutant IDH1 R132 h inhibitor with IC50 < 0.1 uM.
T12128 Mutant IDH1-IN-2 1429176-69-1 98%
Mutant IDH1-IN-2 is a mutant Isocitrate dehydrogenase (IDH) proteins inhibitor
T2104 AGI-5198 1355326-35-0 98%
AGI-5198 is a highly effective and specific inhibitor of IDH1 R132H/R132C mutants (IC50: 0.07/0.16 μM).
T16384 Olutasidenib 1887014-12-1 98%
Olutasidenib is under the study in the treatment of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Olutasidenib is a highly effective, brain pen...
TQ0042 BAY-1436032 1803274-65-8 98%
BAY-1436032 is a novel, selective and orally available inhibitor of pan-mutant isocitrate dehydrogenase 1 (IDH1).
T3617 Ivosidenib 1448347-49-6 98%
Ivosidenib is an orally available inhibitor of isocitrate dehydrogenase type 1 (IDH1), with potential antineoplastic activity. Ivosidenib specifically inhibits a...
T2346 Enasidenib 1446502-11-9 98%
Enasidenib is an orally available inhibitor of specific mutant forms of the mitochondrial enzyme isocitrate dehydrogenase type 2 (IDH2), with potential antineopl...
DS-1001b
T7741
DS-1001b is an inhibitor of mutant IDH-1 (Isocitrate Dehydrogenase-1)
Mutant IDH1 inhibitor
T16161
Mutant IDH1 inhibitor is an effective inhibitor of mutant IDH1 R132H (IC50: < 72 nM).
Vorasidenib
T7307
Vorasidenib is an inhibitor of mutant isocitrate dehydrogenase (IDH; IC50s = 31.9 and 31.7 nM for IDH1R132H and IDH2R140Q, respectively)
AGI-6780
T1809
AGI-6780 is a potent and selective inhibitor of IDH2 R140Q mutant.
Mutant IDH1-IN-1
T2043
Mutant IDH1-IN-1 is a potent mutant IDH1 R132 h inhibitor with IC50 < 0.1 uM.
Mutant IDH1-IN-2
T12128
Mutant IDH1-IN-2 is a mutant Isocitrate dehydrogenase (IDH) proteins inhibitor
AGI-5198
T2104
AGI-5198 is a highly effective and specific inhibitor of IDH1 R132H/R132C mutants (IC50: 0.07/0.16 μM).
Olutasidenib
T16384
Olutasidenib is under the study in the treatment of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Olutasidenib is a highly effective, brain pen...
BAY-1436032
TQ0042
BAY-1436032 is a novel, selective and orally available inhibitor of pan-mutant isocitrate dehydrogenase 1 (IDH1).
Ivosidenib
T3617
Ivosidenib is an orally available inhibitor of isocitrate dehydrogenase type 1 (IDH1), with potential antineoplastic activity. Ivosidenib specifically inhibits a...
Enasidenib
T2346
Enasidenib is an orally available inhibitor of specific mutant forms of the mitochondrial enzyme isocitrate dehydrogenase type 2 (IDH2), with potential antineopl...